Edition:
United States

Moleculin Biotech Inc (MBRX.A)

MBRX.A on American Stock Exchange

1.20USD
14 Jun 2019
Change (% chg)

-- (--)
Prev Close
$1.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,821
52-wk High
$3.13
52-wk Low
$0.87

Latest Key Developments (Source: Significant Developments)

Moleculin Biotech Reports Qtrly Loss Per Share Of $0.14
Tuesday, 14 May 2019 07:30am EDT 

May 14 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH, INC. REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2019.MOLECULIN BIOTECH INC QTRLY LOSS PER SHARE $0.14.MOLECULIN BIOTECH INC - AS OF MARCH 31, 2019, COMPANY HAD CASH AND CASH EQUIVALENTS OF $8.8 MILLION.MOLECULIN BIOTECH - BELIEVES THAT EXISTING CASH & CASH EQUIVALENTS AS OF MARCH 31, 2019 WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO Q2 OF 2020.MOLECULIN BIOTECH INC - BELIEVES EXISTING CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2019 TO BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO Q2 OF 2020.  Full Article

Moleculin Biotech Inc Reports Financial Results For The Year Ended December 31, 2018
Thursday, 21 Feb 2019 04:59pm EST 

Feb 21 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH, INC. REPORTS FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2018.MOLECULIN BIOTECH INC - AS OF DECEMBER 31, 2018, HAD CASH AND CASH EQUIVALENTS OF $7.1 MILLION AND PREPAID EXPENSES AND OTHER OF $0.9 MILLION.MOLECULIN BIOTECH-BELIEVE CASH RESOURCES AS OF DEC 31, 2018, ADDITIONAL FUNDING WILL BE SUFFICIENT TO MEET OUR PROJECTED OPERATING NEEDS INTO Q3 2019.  Full Article

Moleculin Announces The FDA Has Granted Orphan Drug Designation For Its Brain Tumor Drug
Tuesday, 5 Feb 2019 07:30am EST 

Feb 5 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES THE FDA HAS GRANTED ORPHAN DRUG DESIGNATION FOR ITS BRAIN TUMOR DRUG.  Full Article

Moleculin Announces Patient Recruitment Begins In Annamycin Clinical Trial In Poland
Wednesday, 9 Jan 2019 07:30am EST 

Jan 9 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES PATIENT RECRUITMENT BEGINS IN ANNAMYCIN CLINICAL TRIAL IN POLAND.MOLECULIN BIOTECH INC - RECEIVED EUROPEAN APPROVAL TO SHIP ANNAMYCIN INTO POLAND TO START TREATING PATIENTS.  Full Article

Moleculin Enters Agreement With BSP Pharmaceuticals For Its Leukemia Drug Candidate
Tuesday, 24 Apr 2018 08:30am EDT 

April 24 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ENTERS AGREEMENT WITH BSP PHARMACEUTICALS FOR ITS LEUKEMIA DRUG CANDIDATE.MOLECULIN BIOTECH INC - ENGAGED BSP PHARMACEUTICALS S.P.A. TO BEGIN PREPARATIONS FOR COMMERCIAL SCALE PRODUCTION OF ANNAMYCIN DRUG PRODUCT.  Full Article

Moleculin Biotech Reports Financial Results For The Year Ended Dec 31, 2017
Wednesday, 28 Mar 2018 08:30am EDT 

March 28 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH, INC. REPORTS FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2017.MOLECULIN BIOTECH - BELIEVES EXISTING CASH & CASH EQUIVALENTS AS OF DECEMBER 31, 2017, OTHER CASH, WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO Q1 2019.  Full Article

Moleculin Announces Pricing Of $9 Million Registered Direct Offering
Friday, 16 Feb 2018 08:29am EST 

Feb 16 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES PRICING OF $9 MILLION REGISTERED DIRECT OFFERING.MOLECULIN BIOTECH - ‍IN CONNECTION WITH OFFERING, CO WILL ISSUE 4.3 MILLION REGISTERED SHARES OF COMMON STOCK AT A PURCHASE PRICE OF $2.10 PER SHARE​.  Full Article

Moleculin Announces Discovery Of A New Molecule For Cancer Treatment
Thursday, 15 Feb 2018 08:30am EST 

Feb 15 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH INC - ANNOUNCES BREAKTHROUGH IN ITS EFFORT TO DEVELOP A NEW CANCER TREATMENT THAT SELECTIVELY KILLS HIGHLY RESISTANT TUMORS​.  Full Article

Moleculin Announces Polish Approval For Leukemia Clinical Trial
Thursday, 21 Dec 2017 08:30am EST 

Dec 21 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES POLISH APPROVAL FOR LEUKEMIA CLINICAL TRIAL.MOLECULIN BIOTECH - ETHICS COMMITTEE IN POLAND HAS APPROVED COMPANY'S PHASE I/II CLINICAL TRIAL OF ANNAMYCIN FOR TREATMENT OF LEUKEMIA.MOLECULIN BIOTECH INC - COMPANY EXPECTS FIRST PATIENT TO BE ENROLLED IN Q1 2018.MOLECULIN BIOTECH - BELIEVES CLINICAL DATA PRODUCED IN POLAND WILL BE USEFUL IN INTERACTIONS WITH U.S. FDA, EUROPEAN MEDICINES AGENCY.  Full Article

Moleculin's WP1066 Drug Gets FDA Brain Tumor IND Clearance
Tuesday, 5 Dec 2017 07:00am EST 

Dec 5 (Reuters) - Moleculin Biotech Inc ::MOLECULIN'S WP1066 DRUG GETS FDA BRAIN TUMOR IND CLEARANCE.MOLECULIN BIOTECH-IND APPLICATION FOR PHASE I TRIAL OF WP1066 IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA, BRAIN METASTASIS FROM MELANOMA, ALLOWED BY FDA.  Full Article